Bioprocess Development and Characterization of a C-Labeled Hybrid Bispecific Antibody Produced in .

Antibodies (Basel)

Cell Culture and Bioprocess Operations, Genentech Inc., South San Francisco, CA 94080, USA.

Published: February 2023

Monoclonal antibodies (mAbs) are highly efficacious therapeutics; however, due to their large, dynamic nature, structural perturbations and regional modifications are often difficult to study. Moreover, the homodimeric, symmetrical nature of mAbs makes it difficult to elucidate which heavy chain (HC)-light chain (LC) pairs are responsible for any structural changes, stability concerns, and/or site-specific modifications. Isotopic labeling is an attractive means for selectively incorporating atoms with known mass differences to enable identification/monitoring using techniques such as mass spectrometry (MS) and nuclear magnetic resonance (NMR). However, the isotopic incorporation of atoms into proteins is typically incomplete. Here we present a strategy for incorporating C-labeling of half antibodies using an fermentation system. Unlike previous attempts to generate isotopically labeled mAbs, we provide an industry-relevant, high cell density process that yielded >99% C-incorporation using C-glucose and C-celtone. The isotopic incorporation was performed on a half antibody designed with knob-into-hole technology to enable assembly with its native (naturally abundant) counterpart to generate a hybrid bispecific (BsAb) molecule. This work is intended to provide a framework for producing full-length antibodies, of which half are isotopically labeled, in order to study the individual HC-LC pairs.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944054PMC
http://dx.doi.org/10.3390/antib12010016DOI Listing

Publication Analysis

Top Keywords

hybrid bispecific
8
isotopic incorporation
8
isotopically labeled
8
bioprocess development
4
development characterization
4
characterization c-labeled
4
c-labeled hybrid
4
bispecific antibody
4
antibody produced
4
produced monoclonal
4

Similar Publications

Leuco-malachite green (LMG) and leuco-crystal violet (LCV) are widespread co-pollutants in aquatic products that pose a severe threat to human health. Therefore, it is urgent and challenging to develop rapid multiplex detection of LMG and LCV. Herein, the bispecific aptamer (A5b) for LMG and LCV was characterized.

View Article and Find Full Text PDF

Non-small cell lung cancers (NSCLC) frequently acquire resistance to tyrosine kinase inhibitors (TKI) due to epidermal growth factor receptor (EGFR) mutation or activation of the bypass pathway involving mesenchymal-epithelial transition factor (Met). To address this challenge, a bispecific nanobody-aptamer chimera is designed to target mutated EGFR and Met simultaneously to block their cross-talk in NSCLC. The EGFR-Met chimera is cost-effectively engineered using microbial transglutaminase and click chemistry strategies.

View Article and Find Full Text PDF

We present a detailed mass spectrometric analysis of three 2 + 1 T-cell bispecific monoclonal antibodies (TCB mAbs), where an unexpected +15.9950 Da mass shift in tryptic peptides was observed. This modification was attributed to the occurrence of 5R-hydroxylysine (Hyl) using a hybrid LC-MS/MS molecular characterization and CRISPR/Cas9 gene deletion approach.

View Article and Find Full Text PDF

The development of novel tools to tackle viral processes has become a central focus in global health, during the COVID-19 pandemic. The spike protein is currently one of the main SARS-CoV-2 targets, owing to its key roles in infectivity and virion formation. In this context, exploring innovative strategies to block the activity of essential factors of SARS-CoV-2, such as spike proteins, will strengthen the capacity to respond to current and future threats.

View Article and Find Full Text PDF
Article Synopsis
  • Double-hit lymphoma (DHL) is a high-risk type of large B-cell lymphoma characterized by specific genetic rearrangements and is diagnosed using histology, immunophenotyping, and FISH techniques.
  • * DHL can vary in appearance and is typically of the germinal center B-cell type, with prognosis affected by factors like elevated LDH levels and disease stage.
  • * Advances in treatment, including intensive chemotherapy and innovative therapies like CAR-T cells, show promise for improving outcomes, especially in cases that are resistant to standard therapies.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!